Share prices change all the time, giving investors opportunities to buy and achieve strong returns. Experts have picked out some ASX shares that could deliver substantial returns.

Analysts tell investors what they think a business’ potential returns could be, along with a price target. The price target is the level analysts expect the share price to reach 12 months from the date of the investment rating.

Below are two ASX shares that experts think could deliver strong, potentially market-beating returns.

Regis Healthcare Ltd (ASX: REG)

Regis Healthcare is one of the largest aged care operators in Australia. It provides services to more than 10,000 older Australians through residential aged care homes, home care service hubs, day therapy, respite centres, and retirement villages.

According to CMC Invest, there have been six analyst ratings on the business within the last three months. The average price target is $6.08, implying that those six analysts collectively think the Regis Healthcare share price could rise by almost 40% over the next 12 months.

The Regis Healthcare share price has fallen around 30% since the end of August 2026 amid news that government funding is not going to rise as much as hoped in the year ahead, despite elevated inflation of costs.

To combat this, the ASX share is undertaking a range of initiatives to mitigate the margin pressures associated with government funding settings. Some of those ideas include increases to room prices, a rollout of higher everyday living fee (HELF) services, other revenue optimisation, and operational efficiency initiatives.

On top of that, there is the long-term tailwind of ageing demographics, which can increase the demand for aged care.

Based on the projection on CMC Invest, Regis Healthcare is currently priced at 18 times FY28’s estimated earnings at the time of writing.

Pinnacle Investment Management Group Ltd (ASX: PNI)

The other ASX share I want to highlight is Pinnacle. It says that it’s growing a diverse family of investment businesses (which Pinnacle calls affiliates).

While holding a stake in affiliates, it provides seed funding, global institutional and retail distribution, and industrial grade middle office and infrastructure services. By providing affiliates with quality non-investment services, Pinnacle enables them to focus on generating investment returns for clients.  

Some of the affiliates it’s invested in include Hyperion, Plato, Palisade, Resolution Capital, Solaris, Antipodes, Spheria, Firetrail, Coolabah, Pacific Asset Management, Life Cycle, and so on.

According to CMC Invest, there have been six analyst ratings on the business within the last six months. The average price target from those six analysts is $21.76, implying a potential 55% rise in the year ahead.

Volatility in the ASX share market and private credit sector may have impacted investor confidence, so a potential recovery in investor bullishness could help deliver a lot of the return. Time will tell how the uncertainty with private credit plays out for Pinnacle’s affiliate FUM.

According to CMC Invest, the business is valued at 16 times FY27’s estimated earnings.

The post 2 ASX shares tipped to grow up to 55% or more in the next 12 months appeared first on The Motley Fool Australia.

More reading

• 6 ASX shares upgraded by experts amid a weak market 
• Here are the top 10 ASX 200 shares today
• Pinnacle Investment Management reports FY26 profit and Metrics funds update
• 1 ASX dividend stock down 47% I’d buy right now
• 1 ASX dividend stock down 49% I’d buy right now

Motley Fool contributor Tristan Harrison has positions in Pinnacle Investment Management Group. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Pinnacle Investment Management Group. The Motley Fool Australia has positions in and has recommended Pinnacle Investment Management Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Deciding which ASX 200 shares are buys and which ones are sells can be difficult. 

To help you work things out, let’s look at three shares that experts are tipping as sells this week, courtesy of The Bull. 

Here’s what they are recommending:

ANZ Group Holdings Ltd (ASX: ANZ)

The team at Lazarus Capital Partners has named ANZ shares as a sell this week.

It has concerns with how the weakening housing market could impact lending growth and credit quality. Lazarus said: 

The bank faces headwinds as Australian house prices fall. After acquiring Suncorp Bank, ANZ is the country’s third largest home lender. The bank noted a 12 per cent fall in home loan application values since the May budget and the end of July following the Federal Government’s proposed changes to negative gearing and capital gains tax. 

Capital city house prices may fall more than 10 per cent from their peak, raising negative equity risks among recent low deposit buyers, which may pressure lending growth and credit quality. Investors may want to consider cashing in some gains given the share price rise since June.

Commonwealth Bank of Australia (ASX: CBA)

Over at Medallion Financial Group, it has named CBA shares as a sell.

Its team has concerns over the company’s valuation and thinks investors should be re-allocating capital to other areas of the market that offer more attractive potential returns. Medallion explains:

This bank delivered another strong result in full year 2026. The company posted cash profit of $10.982 billion in full year 2026, up 7 per cent on the prior corresponding period. The full year dividend of $5.05, fully franked, was up 4 per cent. CBA’s scale, customer franchise and technology investment underpin the company’s quality. 

Nevertheless, we believe the valuation leaves insufficient room for disappointment. Mortgage competition, operating costs and the potential for credit losses to normalise remain risks. We favour taking profits and re-allocating capital to other companies where earnings growth and income offer a more compelling prospective return.

Evolution Mining Ltd (ASX: EVN)

Gray Perry Wealth Advisers thinks that gold miner Evolution Mining could be an ASX 200 share to sell this week.

It thinks that recent share price strength means that there is limited room for operational setbacks or weaker metal prices. The wealth adviser explains:

Evolution Mining produces gold and copper from operations in Australia and Canada. The company delivered record cash generation, a net cash position and higher shareholder returns in full year 2026, supported by strong gold and copper prices. However, sustaining record earnings relies on gold and copper prices remaining high in a volatile world. 

Future performance depends on consistent delivery across major operations, disciplined investment and continuing replacement of mined reserves. After a recent and substantial share price recovery, the valuation leaves limited room for operational setbacks or weaker metal prices. Investors may want to consider taking profits at current levels.

The post Experts tip CBA and these ASX 200 shares as sells appeared first on The Motley Fool Australia.

More reading

• CBA vs Coles shares: Which is the better buy at age 50?
• How many CBA shares do I need to buy for $10,000 of passive income?
• CSL vs CBA: Which ASX share is best for SMSFs?
• 5 things to watch on the ASX 200 on Friday
• If I invest $8,000 in CBA shares, what passive income could I earn in FY27 and FY28?

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

For a long time, growth at a reasonable price, or GARP, was probably the investment style I was most naturally drawn to.

This meant finding ASX shares capable of growing earnings at attractive rates, but avoiding paying a price that assumes too much of that growth in advance.

I still like that approach. But these days, I prefer quality at a reasonable price, or QARP.

With GARP, growth tends to be the starting point. With QARP, I start with the quality of the business.

I want ASX shares with strong competitive positions, attractive economics, healthy balance sheets, good cash generation, and the ability to keep reinvesting for years. Only then do I ask whether the valuation leaves enough room for an attractive return.

Why the shift? Because growth can disappear quickly. A fast-growing company can slow or lose market share. A genuinely high-quality business has a better chance of handling setbacks and continuing to create value.

That does not mean valuation becomes less important. A wonderful business can still be a poor investment if its share price already assumes a near-perfect future.

So, I recently screened the ASX 200 looking for shares offering both quality and a valuation I believe can still support attractive long-term returns.

Five stood out.

CAR Group Limited (ASX: CAR)

The first is CAR Group. I think this ASX share is a very good example of what I mean by QARP.

It operates leading automotive marketplaces across Australia and several international markets, giving it strong local economics and a longer runway offshore.

One of its biggest strengths is its network effects. Buyers gravitate towards marketplaces with the most listings, while sellers want to advertise where the buyers already are. Once that position is established, it becomes difficult for a new competitor to recreate the same audience.

CAR Group can then use that position to improve monetisation, launch new products, and grow internationally without requiring the physical capital many traditional businesses need.

I also like that the investment case is no longer resting on Australia alone. Its businesses in the United States, Brazil, and South Korea give the group several avenues for expansion.

Weaker economic conditions could reduce vehicle activity. But I think the strength of the platform, its cash generation, and its international opportunity make CAR Group a compelling long-term investment option.

And despite making my final five, it was not the opportunity that stood out most from the screen.

The remaining four include ASX shares where I think the market may be underestimating the quality or recovery potential, as well as one name that I believe currently offers the best overall QARP setup of the group.

CSL Ltd (ASX: CSL)

CSL is probably the clearest example here of a high-quality business that has fallen out of favour.

The biotechnology giant has disappointed investors in recent years. Execution has not always matched expectations and margins have faced pressure.

But I think the key question is whether those issues have permanently damaged the underlying business.

The good news is that I don’t believe they have.

CSL Behring has enormous scale in plasma collection and the manufacture of therapies used to treat serious and often rare diseases. It also has decades of expertise and a global collection network that would be extremely difficult to replicate.

Demand for many of its therapies is relatively resilient.

A recovery may not be immediate, but at a touch over 17 times estimated FY 2029 earnings, I think the share price now reflects far more caution than it once did.

If management can improve execution and margins while underlying demand keeps growing, CSL could offer strong returns from here.

Goodman Group (ASX: GMG)

Goodman Group is another ASX share that I think deserves its reputation for quality.

It is often described as an industrial property group, but that does not really cover the full opportunity.

Goodman specialises in securing land, power, planning approvals, and development opportunities in locations where major customers want logistics and digital infrastructure.

That has become incredibly valuable as demand for data centres has accelerated.

Artificial intelligence (AI) and cloud computing require enormous amounts of computing capacity, which is creating demand for sites with access to power and major population centres.

Goodman’s footprint and development expertise give it an advantage, while its partnership model allows it to keep recycling capital into new opportunities.

Its shares rarely look cheap and expectations around data centres are already high. But I think recent share price weakness has created an attractive entry point.

REA Group Ltd (ASX: REA)

REA Group is another ASX share that oozes quality.

Its realestate.com.au platform has an exceptionally strong position in the Australian property market.

Buyers want to search where the largest number of properties are listed, while agents and vendors want to advertise where the buyers are. That creates a powerful network effect and makes the platform difficult to displace.

REA also benefits from attractive economics. Advertising a property can represent a small percentage of a transaction’s value, yet reaching the largest pool of buyers is highly important to the seller. That gives the company significant pricing power.

Listings will still rise and fall with the housing cycle. And with interest rates rising, the cycle is certainly going through a tough stretch.

But for a long-term investor, I think the bigger consideration is whether REA will still be central to how Australians search for property in another decade.

I believe it will. That is why, despite a valuation that is unlikely to look conventionally cheap, I still think REA can fit within a QARP framework.

ResMed Inc (ASX: RMD)

The final ASX share is ResMed.

Of the five, I think this one currently offers the strongest combination of quality, valuation, and expected return.

ResMed is a global leader in devices, masks, and software used to treat sleep apnoea.

What I like most is that the company still has a huge market opportunity even after decades of growth. Sleep apnoea already affects a huge number of people, but the vast majority remain undiagnosed or untreated.

As diagnosis improves and treatment rates rise, ResMed stands to benefit from more patients entering the system.

There is also an attractive recurring element to the model. Masks and other consumables need replacing, creating ongoing demand.

At around 19 times estimated FY 2027 earnings, I think its valuation is compelling relative to the quality of the business and the runway ahead. That is what I want from a QARP investment.

Final word

I am not trying to find the cheapest shares on the ASX. 

I would much rather own a great business at a sensible price than an average one simply because its shares look inexpensive.

CAR Group, CSL, Goodman, REA, and ResMed all meet that test for me in different ways.

The post I screened the ASX for quality and value. These 5 shares stood out appeared first on The Motley Fool Australia.

More reading

• CSL vs CBA: Which ASX share is best for SMSFs?
• 3 ASX 200 shares I think could rise more than 10% in a year
• 4 ASX shares tipped by brokers to return 18% to 96%
• CAR Group vs Seek: Which ASX 200 stock is better value?
• 3 ASX shares to buy amid a volatile market: experts

Motley Fool contributor James Mickleboro has positions in CSL, Goodman Group, REA Group, and ResMed. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL, Goodman Group, and ResMed. The Motley Fool Australia has positions in and has recommended Goodman Group and ResMed. The Motley Fool Australia has recommended CAR Group Ltd and CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.